Oteracil
As of the edition of 20 October 2026, Oteracil is a small molecule: marketed, first approved in 1999 (JP); acts on UMPS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Teysuno
- First approved
- 1 March 1999 (JP)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Nordic; 2 holders in all
- Registered trials
- 53, 5 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Hormones; Mouth and teeth; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Oteracil.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| UMPS | Uridine 5'-monophosphate synthase | P11172 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 32 | 3 | 9 | 3 |
| Phase 3 | 19 | 7 | 5 | 2 |
| All trials | 53 |